CombiMatrix Corporation (CBMX)
-NasdaqCM 3.19 
0.02(0.62%) 11:52AM EDT - Nasdaq Real Time Price
| Prev Close: | 3.21 |
|---|
| Open: | 3.23 |
|---|
| Bid: | 3.17 x 12800 |
|---|
| Ask: | 3.23 x 100 |
|---|
| 1y Target Est: | 15.00 |
|---|
| Beta: | 0.49 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.17 - 3.27 |
|---|
| 52wk Range: | 1.40 - 14.14 |
|---|
| Volume: | 39,567 |
|---|
| Avg Vol (3m): | 544,838 |
|---|
| Market Cap: | 9.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -6.16 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- COMBIMATRIX CORP FinancialsEDGAR Online Financials(Tue May 21)
- COMBIMATRIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon May 13)
- CombiMatrix Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed May 8)
- Q1 2013 Combimatrix Earnings Release - Before Market OpenCCBN(Wed May 8)
- CombiMatrix Corporation Reports Results for 2013 First QuarterGlobeNewswire(Wed May 8)
- COMBIMATRIX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue May 7)
- CombiMatrix Executes Equity FinancingGlobeNewswire(Mon May 6)
- COMBIMATRIX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Sun May 5)
- COMBIMATRIX CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri May 3)
- CombiMatrix Corporation to Release First Quarter Financial Results on May 8, 2013GlobeNewswire(Wed May 1)
- 5 Health Care Stocks Under $10 Ready to Rip Higherat TheStreet(Thu Apr 18)
- COMBIMATRIX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Mon Apr 8)
- Stocks to Watch: CombiMatrix, Merrimack, Compuwareat The Wall Street Journal(Thu Apr 4)
- CombiMatrix reports Q1 growth in prenatal testing volumes of 124%at theflyonthewall.com(Thu Apr 4)
- CombiMatrix Reports Preliminary Quarterly Growth in Prenatal Testing Volumes of 124% for First QuarterGlobeNewswire(Thu Apr 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.64 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-10)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the field of genetic analysis and molecular diagnostics. The company, through its subsidiary, CombiMatrix Molecular Diagnostics, Inc., operates a diagnostics reference...
View More